A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia

References

• Jayavelu AK, Wolf S, Buettner F, et al. The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell. 2022;40(3):301–317 e12. doi:10.1016/j.ccell.2022.02.006
   PubMed Web of Science ®Google Scholar
• Guieze R, Liu VM, Rosebrock D, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36(4):369–384 e13. doi:10.1016/j.ccell.2019.08.005
   PubMed Web of Science ®Google Scholar
• Baryawno N, Przybylski D, Kowalczyk MS, et al. A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell. 2019;177(7):1915–1932 e16. doi:10.1016/j.cell.2019.04.040
   PubMed Web of Science ®Google Scholar
• Han L, Xu J, Xu Q, et al. Extracellular vesicles in the tumor microenvironment: therapeutic resistance, clinical biomarkers, and targeting strategies. Med Res Rev. 2017;37(6):1318–1349. doi:10.1002/med.21453
   Web of Science ®Google Scholar
• Park HS, Cetin E, Siblini H, et al. Therapeutic potential of mesenchymal stem cell-derived extracellular vesicles to treat PCOS. Int J Mol Sci. 2023;24(13):11151. doi:10.3390/ijms241311151
   PubMed Web of Science ®Google Scholar
• Malekpour K, Hazrati A, Zahar M, et al. The potential use of mesenchymal stem cells and their derived exosomes for orthopedic diseases treatment. Stem Cell Rev Rep. 2022;18(3):933–951. doi:10.1007/s12015-021-10185-z
   PubMed Web of Science ®Google Scholar
• Guo W, Gao Y, Li N, et al. Exosomes: new players in cancer (review). Oncol Rep. 2017;38(2):665–675. doi:10.3892/or.2017.5714
   Web of Science ®Google Scholar
• Kumar B, Garcia M, Murakami JL, et al. Exosome-mediated microenvironment dysregulation in leukemia. Biochim Biophys Acta. 2016;1863(3):464–470. doi:10.1016/j.bbamcr.2015.09.017
   Web of Science ®Google Scholar
• Amin AH, Sharifi LMA, Kakhharov AJ, et al. Role of acute myeloid leukemia (AML)-derived exosomes in tumor progression and survival. Biomed Pharmacother. 2022;150:113009. doi:10.1016/j.biopha.2022.113009
   Web of Science ®Google Scholar
• Wojtuszkiewicz A, Schuurhuis GJ, Kessler FL, et al. Exosomes secreted by apoptosis-resistant acute myeloid leukemia (AML) blasts harbor regulatory network proteins potentially involved in antagonism of apoptosis. Mol Cell Proteomics. 2016;15(4):1281–1298. doi:10.1074/mcp.M115.052944
   PubMed Web of Science ®Google Scholar
• Farooqi AA, Desai NN, Qureshi MZ, et al. Exosome biogenesis, bioactivities and functions as new delivery systems of natural compounds. Biotechnol Adv. 2018;36(1):328–334. doi:10.1016/j.biotechadv.2017.12.010
   PubMed Web of Science ®Google Scholar
• Chitadze G, Bhat J, Lettau M, et al. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol. 2013;78(2):120–129. doi:10.1111/sji.12072
   PubMed Web of Science ®Google Scholar
• Bobrie A, Colombo M, Raposo G, et al. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic. 2011;12(12):1659–1668. doi:10.1111/j.1600-0854.2011.01225.x
   PubMed Web of Science ®Google Scholar
• Szajnik M, Czystowska M, Szczepanski MJ, et al. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010;5(7):e11469. doi:10.1371/journal.pone.0011469
   PubMed Web of Science ®Google Scholar
• Valenti R, Huber V, Filipazzi P, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006;66(18):9290–9298. doi:10.1158/0008-5472.CAN-06-1819
   PubMed Web of Science ®Google Scholar
• Wang J, Sun X, Zhao J, et al. Exosomes: a novel strategy for treatment and prevention of diseases. Front Pharmacol. 2017;8:300. doi:10.3389/fphar.2017.00300
   PubMed Web of Science ®Google Scholar
• Wang J, De Veirman K, De Beule N, et al. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget. 2015;6(41):43992–44004. doi:10.18632/oncotarget.6083
   PubMedGoogle Scholar
• Lee CH, Bae JH, Choe EJ, et al. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1. Theranostics. 2022;12(5):1971–1987. doi:10.7150/thno.68864
   Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–416 e11. doi:10.1016/j.cell.2018.02.052
   PubMed Web of Science ®Google Scholar
• Pathan M, Fonseka P, Chitti SV, et al. Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2019;47(D1):D516–D519. doi:10.1093/nar/gky1029
   PubMed Web of Science ®Google Scholar
• Kalra H, Simpson RJ, Ji H, et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 2012;10(12):e1001450. doi:10.1371/journal.pbio.1001450
   PubMed Web of Science ®Google Scholar
• van Galen P, Hovestadt V, Wadsworth Ii MH, et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176(6):1265–1281 e24. doi:10.1016/j.cell.2019.01.031
   PubMed Web of Science ®Google Scholar
• Wang H, Lengerich BJ, Aragam B, et al. Precision LASSO: accounting for correlations and linear dependencies in high-dimensional genomic data. Bioinformatics. 2019;35(7):1181–1187. doi:10.1093/bioinformatics/bty750
   PubMed Web of Science ®Google Scholar
• Zou J, Wang E. Cancer biomarker discovery for precision medicine: new progress. Curr Med Chem. 2019;26(42):7655–7671. doi:10.2174/0929867325666180718164712
   Web of Science ®Google Scholar
• Taniguchi N, Kizuka Y. Glycans and cancer: role of N-glycans in cancer biomarker, progression and metastasis, and therapeutics. Adv Cancer Res. 2015;126:11–51. doi:10.1016/bs.acr.2014.11.001
   PubMed Web of Science ®Google Scholar
• Zhang J, Li S, Li L, et al. Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics Proteomics Bioinformatics. 2015;13(1):17–24. doi:10.1016/j.gpb.2015.02.001
   PubMed Web of Science ®Google Scholar
• Andreu Z, Yanez-Mo M. Tetraspanins in extracellular vesicle formation and function. Front Immunol. 2014;5:442. doi:10.3389/fimmu.2014.00442
   PubMed Web of Science ®Google Scholar
• Escola JM, Kleijmeer MJ, Stoorvogel W, et al. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem. 1998;273(32):20121–7. doi:10.1074/jbc.273.32.20121
   PubMed Web of Science ®Google Scholar
• Schwartz-Albiez R, Dorken B, Hofmann W, et al. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol. 1988;140(3):905–914. doi:10.4049/jimmunol.140.3.905
   Web of Science ®Google Scholar
• van Spriel AB, Puls KL, Sofi M, et al. A regulatory role for CD37 in T cell proliferation. J Immunol. 2004;172(5):2953–2961. doi:10.4049/jimmunol.172.5.2953
   Web of Science ®Google Scholar
• van Spriel AB. Tetraspanins in the humoral immune response. Biochem Soc Trans. 2011;39(2):512–517. doi:10.1042/BST0390512
   Google Scholar
• Knobeloch KP, Wright MD, Ochsenbein AF, et al. Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions. Mol Cell Biol. 2000;20(15):5363–5369. doi:10.1128/MCB.20.15.5363-5369.2000
   PubMed Web of Science ®Google Scholar
• van Spriel AB, Sofi M, Gartlan KH, et al. The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity. PLoS Pathog. 2009;5(3):e1000338. doi:10.1371/journal.ppat.1000338
   Web of Science ®Google Scholar
• Link MP, Bindl J, Meeker TC, et al. A unique antigen on mature B cells defined by a monoclonal antibody. J Immunol. 1986;137(9):3013–3018. doi:10.4049/jimmunol.137.9.3013
   Web of Science ®Google Scholar
• Beckwith KA, Frissora FW, Stefanovski MR, et al. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014;28(7):1501–1510. doi:10.1038/leu.2014.32
   Web of Science ®Google Scholar
• Zhang Q, Han Q, Zi J, et al. Cd37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia. Biosci Rep. 2020;40(5):BSR20200008. doi:10.1042/BSR20200008
   Google Scholar
• Lapalombella R, Yeh YY, Wang L, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012;21(5):694–708. doi:10.1016/j.ccr.2012.03.040
   Web of Science ®Google Scholar
• Oksvold MP, Kullmann A, Forfang L, et al. Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells. Clin Ther. 2014;36(6):847–862 e1. doi:10.1016/j.clinthera.2014.05.010
   PubMed Web of Science ®Google Scholar
• Oh IS, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709–712. doi:10.1038/nature05162
   PubMed Web of Science ®Google Scholar
• Schalla MA, Unniappan S, Lambrecht NWG, et al. Nucb2/Nesfatin-1 – inhibitory effects on food intake, body weight and metabolism. Peptides. 2020;128:170308. doi:10.1016/j.peptides.2020.170308
   PubMed Web of Science ®Google Scholar
• Ning S, Liu C, Wang K, et al. Nucb2/Nesfatin-1 drives breast cancer metastasis through the up-regulation of cholesterol synthesis via the mTORC1 pathway. J Transl Med. 2023;21(1):362. doi:10.1186/s12967-023-04236-x
   Web of Science ®Google Scholar
• Ren L, Bao D, Wang L, et al. Nucleobindin-2/Nesfatin-1 enhances the cell proliferation, migration, invasion and epithelial-mesenchymal transition in gastric carcinoma. J Cell Mol Med. 2022;26(19):4986–4994. doi:10.1111/jcmm.17522
   Web of Science ®Google Scholar
• Chen J, Xiao Q, Li X, et al. The correlation of leukocyte-specific protein 1 (LSP1) rs3817198(T > C) polymorphism with breast cancer: a meta-analysis. Medicine. 2022;101(45):e31548. doi:10.1097/MD.0000000000031548
   Web of Science ®Google Scholar
• Koral K, Bhushan B, Orr A, et al. Lymphocyte-specific protein-1 suppresses xenobiotic-induced constitutive androstane receptor and subsequent yes-associated protein-activated hepatocyte proliferation. Am J Pathol. 2022;192(6):887–903. doi:10.1016/j.ajpath.2022.03.010
   Web of Science ®Google Scholar
• Kwon R, Hong BK, Lee KG, et al. Regulation of tumor growth by leukocyte-specific protein 1 in T cells. J Immunother Cancer. 2020;8(2):e001180. doi:10.1136/jitc-2020-001180
   Web of Science ®Google Scholar
• Kelner MJ, Bagnell RD, Montoya MA, et al. Structural organization of the microsomal glutathione S-transferase gene (MGST1) on chromosome 12p13.1–13.2. Identification of the correct promoter region and demonstration of transcriptional regulation in response to oxidative stress. J Biol Chem. 2000;275(17):13000–13006. doi:10.1074/jbc.275.17.13000
   Web of Science ®Google Scholar
• Morgenstern R, Zhang J, Johansson K. Microsomal glutathione transferase 1: mechanism and functional roles. Drug Metab Rev. 2011;43(2):300–306. doi:10.3109/03602532.2011.558511
   PubMed Web of Science ®Google Scholar
• Zeng B, Ge C, Li R, et al. Knockdown of microsomal glutathione S-transferase 1 inhibits lung adenocarcinoma cell proliferation and induces apoptosis. Biomed Pharmacother. 2020;121:109562. doi:10.1016/j.biopha.2019.109562
   PubMed Web of Science ®Google Scholar
• Kuang F, Liu J, Xie Y, et al. Mgst1 is a redox-sensitive repressor of ferroptosis in pancreatic cancer cells. Cell Chem Biol. 2021;28(6):765–775 e5. doi:10.1016/j.chembiol.2021.01.006
   PubMed Web of Science ®Google Scholar
• Li Y, Xu X, Wang X, et al. Mgst1 expression is associated with poor prognosis, enhancing the Wnt/beta-catenin pathway via regulating AKT and inhibiting ferroptosis in gastric cancer. ACS Omega. 2023;8(26):23683–23694. doi:10.1021/acsomega.3c01782
   Google Scholar
• Rody A, Karn T, Ruckhaberle E, et al. Loss of plexin B1 is highly prognostic in low proliferating ER positive breast cancers–results of a large scale microarray analysis. Eur J Cancer. 2009;45(3):405–413. doi:10.1016/j.ejca.2008.10.016
   Web of Science ®Google Scholar
• Rody A, Holtrich U, Gaetje R, et al. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res. 2007;13(4):1115–1122. doi:10.1158/1078-0432.CCR-06-2433
   Web of Science ®Google Scholar
• Shorning B, Trent N, Griffiths DF, et al. Plexin-B1 mutation drives metastasis in prostate cancer mouse models. Cancer Res Commun. 2023;3(3):444–458. doi:10.1158/2767-9764.CRC-22-0480
   Google Scholar
• Delaire S, Billard C, Tordjman R, et al. Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration. J Immunol. 2001;166(7):4348–4354. doi:10.4049/jimmunol.166.7.4348
   PubMed Web of Science ®Google Scholar
• Chabbert-de Ponnat I, Marie-Cardine A, Pasterkamp RJ, et al. Soluble CD100 functions on human monocytes and immature dendritic cells require plexin C1 and plexin B1, respectively. Int Immunol. 2005;17(4):439–447. doi:10.1093/intimm/dxh224
   PubMed Web of Science ®Google Scholar
• Ishida I, Kumanogoh A, Suzuki K, et al. Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses. Int Immunol. 2003;15(8):1027–1034. doi:10.1093/intimm/dxg098
   PubMed Web of Science ®Google Scholar
• Corrado C, Raimondo S, Saieva L, et al. Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells. Cancer Lett. 2014;348(1–2):71–76. doi:10.1016/j.canlet.2014.03.009
   Web of Science ®Google Scholar
• Chen X, Lu Q, Zhou H, et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell. 2023;186(18):3903–3920 e21. doi:10.1016/j.cell.2023.07.016
   Web of Science ®Google Scholar